Your Article Summary
See Latest ArticlesCytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir Therapy
The Journal of Heart and Lung Transplantation, 07/01/09
Jaksch P et al. - A 12-month CMV prophylaxis with oral valganciclovir is effective in significantly reducing CMV viremia and CMV disease/syndrome in high-risk lung transplant recipients. In addition, a reduction in acute and recurrent rejection episodes was observed, possibly due to less CMV viremia and subsequent immunomodulatory effects.
Related Articles
Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis
Graefe's Archive for Clinical and Experimental Ophthalmology, 10/02/09
Relevance Score: 84%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer
Journal of Clinical Oncology, 12/01/09
Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer
Cancer Chemotherapy and Pharmacology, 12/01/09
Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 12/01/09
Today in Transplantation...keeping you current
Receive free subspecialty "5-minute updates" via email
Lung Allocation Score Predicts Survival in Lung Transplantation Patients With Pulmonary Fibrosis
Annals of Thoracic Surgery, 11/24/09
Lung transplantation in the older adult
Aging Health, 11/23/09
Should lung transplantation be performed for patients on mechanical respiratory support? The US experience
The Journal of Thoracic and Cardiovascular Surgery, 11/23/09